Home Nav
Nextech Invest Logo

Suzanne Obenshain

Alfred Scheidegger

Prior to joining Nextech in 2018, Mrs Obenshain was an investment principal at Castanea Partners, Silver Lake Partners and Morgan Stanley Capital Partners, with 12 years of growth equity investing experience in consumer brands, information services, technology and telecom. Prior board seats included Ippolita LLC, Fitness Anywhere / TRX, and the American School of Paris. Mrs Obenshain’s interest in oncology drug discovery was inspired by her experience as a cancer patient benefiting from both traditional chemotherapy and targeted therapy in 2015. Mrs Obenshain earned her Masters in Business Administration with distinction from Harvard Business School and her BA in economics summa cum laude from Dartmouth College, USA.


Personalized Oncology 2019 conference

23.06. – 25.06.2019

Basel, Switzerland

  • 24.07.2019

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives...

  • 18.07.2019

    Blueprint Medicines Announces European Medicines Agency...

  • 15.07.2019

    Neon Therapeutics ’ Personal Neoantigen Vaccine Study...


Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.


* Compulsory fields


Newsletter Registration

Your eMail have been successfully registered.